Answers are grounded in this paper and cite their sources.
Background: Central nervous system (CNS) infections are a major cause of morbidity and mortality in low- and middle-income countries such as Peru. However, their epidemiology is poorly characterized due to a wide range of endemic and opportunistic pathogens involved and limited access to specialized neurodiagnostic testing. Cerebrospinal fluid (CSF) metagenomic next-generation sequencing (mNGS) can detect any pathogen in a single hypothesis-free assay but has largely been confined to reference laboratories in high-income countries due to high cost and infrastructure requirements. We piloted an in-country, research-based CSF mNGS protocol in Lima, Peru, as a proof-of-concept study to assess the feasibility of implementing this approach in a resource-limited setting. Methods: Adults admitted with suspected CNS infection at Hospital Nacional Dos de Mayo, a large public hospital in Lima, were enrolled from August 2024 to April 2025, and approximately 0.5-2 mL of surplus CSF was collected. CSF mNGS (DNA and RNA) was performed in-country on a benchtop sequencer with half-volume library reactions and cloud-based analysis (CZID). Paired sequencing at a significantly higher depth was performed on a subset of samples in the United States for validation. Results: Among 43 participants (median age 48 years; 21% living with HIV), mNGS performed in Peru detected 20 pathogens in 18 samples (42%), of which 65% were not identified by routine clinical testing. Nine of 15 patients treated empirically for tuberculous meningitis were found to have a non-mycobacterial infection. Detected organisms included Toxoplasma gondii, Taenia solium, Treponema pallidum, human T-lymphotropic virus 1, herpesviruses, and, on deeper sequencing, Venezuelan equine encephalitis virus. Deep sequencing yielded 3.7-fold (DNA) and 6.9-fold (RNA) more reads and recovered four pathogens missed at shallower-depth. Conclusions: In-country CSF mNGS was feasible in Lima, Peru and recovered a clinically and epidemiologically meaningful spectrum of CNS pathogens, most missed by routine testing. By utilizing available, lower-output sequencers, we overcame a principal barrier to deploying this technology where the burden of undiagnosed CNS infection is greatest.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: